Clenoliximab Biosimilar, CD4 Monoclonal Antibody

Clenoliximab Biosimilar uses the same protein sequences as the therapeutic antibody clenoliximab. Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis. Clenoliximab is a macaque-human chimeric monoclonal antibody (immunoglobulin G4)that binds specifically to the CD4 receptor present on T-lympocytes (Helper T lymphocytes). CD-4 lymphocytes are implicated in the pathogenesis of rheumatoid arthritis (RA). Clenoliximab coats the CD4 T-lymphocytes and thus down-modulates the CD4 T-lympocytes in a dose and concentration-dependent manner without decreasing the amount of CD4 T-lympocytes in circulation.

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG4 kappa
Class	Monoclonal
Type	Antibody
Immunogen	The human CD4
Clone	Clenoliximab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	~150kD
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered PBS solution, pH 7.4